merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Lower price and FDA approval</answer>

<question_number>2</question_number>
<answer>Direct competition through a telehealth platform</answer>

<question_number>3</question_number>
<answer>Lack of oversight and safety concerns</answer>

<question_number>4</question_number>
<answer>To regain market share from compounding pharmacies</answer>

<question_number>5</question_number>
<answer>It allows compounding pharmacies to operate legally</answer>

<question_number>6</question_number>
<answer>Removal of third-party supply chain entities</answer>

<question_number>7</question_number>
<answer>Increased use by Medicare patients despite risks</answer>

<question_number>8</question_number>
<answer>Improved safety perceptions</answer>

<question_number>9</question_number>
<answer>FDA shortage list</answer>

<question_number>10</question_number>
<answer>Lower pricing</answer>